Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 3
2020 1
2021 3
2022 5
2023 4
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P, Bourlière M, Di Beo V, Lusivika-Nzinga C, Ramier C, Antwerpes S, Protopopescu C, Lacombe JM, Pol S, Fontaine H, Mourad A, Carrat F, Duracinsky M, Marcellin F; ANRS/AFEF HEPATHER Study Group. Carrieri P, et al. Qual Life Res. 2023 Dec;32(12):3427-3438. doi: 10.1007/s11136-023-03496-w. Epub 2023 Aug 16. Qual Life Res. 2023. PMID: 37587323 Free article.
Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
Lam L, Fontaine H, Lapidus N, Dorival C, Bellet J, Larrey D, Nahon P, Diallo A, Cagnot C, Lusivika-Nzinga C, Téoulé F, Hejblum G, Bourlière M, Pol S, Carrat F; ANRS/AFEF Hepather study group. Lam L, et al. Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):486-495. doi: 10.1002/pds.5576. Epub 2022 Dec 5. Pharmacoepidemiol Drug Saf. 2023. PMID: 36444965
Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort).
Barré T, Pol S, Ramier C, Di Beo V, Carrat F, Bureau M, Bourlière M, Dorival C, Serfaty L, Asselah T, Boursier J, Marcellin F, Carrieri P, Fontaine H, Protopopescu C; ANRS/AFEF Hepather Study Group. Barré T, et al. Cannabis Cannabinoid Res. 2022 Oct;7(5):677-689. doi: 10.1089/can.2021.0094. Epub 2021 Oct 13. Cannabis Cannabinoid Res. 2022. PMID: 34648718 Free PMC article.
Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort.
Lam L, Fontaine H, Lapidus N, Bellet J, Lusivika-Nzinga C, Nicol J, Dorival C, Cagnot C, Hejblum G, Pol S, Bourlière M, Carrat F; ANRS/AFEF HEPATHER Study Group. Lam L, et al. J Viral Hepat. 2023 Mar;30(3):232-241. doi: 10.1111/jvh.13788. Epub 2022 Dec 27. J Viral Hepat. 2023. PMID: 36529681
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.
Barré T, Carrat F, Ramier C, Fontaine H, Di Beo V, Bureau M, Dorival C, Larrey D, Delarocque-Astagneau E, Mathurin P, Marcellin F, Petrov-Sanchez V, Cagnot C, Carrieri P, Pol S, Protopopescu C; ANRS/AFEF Hepather study group. Barré T, et al. J Cannabis Res. 2022 Jun 11;4(1):31. doi: 10.1186/s42238-022-00138-9. J Cannabis Res. 2022. PMID: 35690798 Free PMC article.
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-Nzinga C, Leroy V, De Ledinghen V, Tran A, Zoulim F, Alric L, Gournay J, Bronowicki JP, Decaens T, Riachi G, Mikhail N, Soliman R, Shiha G, Pol S, Carrat F, Ganne-Carrié N; ANRS-AFEF Hepather Study group. Azzi J, et al. Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101923. doi: 10.1016/j.clinre.2022.101923. Epub 2022 Apr 9. Clin Res Hepatol Gastroenterol. 2022. PMID: 35405354 Free article.
Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF, Lapidus N, Dorival C, Diallo A, Amri I, Fontaine H, Pol S, Carrat F; ANRS/AFEF HEPATHER study group. Feldman SF, et al. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):797-805. doi: 10.1002/pds.4552. Epub 2018 May 11. Pharmacoepidemiol Drug Saf. 2018. PMID: 29749668
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D'Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E, Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F; ANRS/AFEF HEPATHER study group. Pol S, et al. J Hepatol. 2017 Jan;66(1):39-47. doi: 10.1016/j.jhep.2016.08.021. Epub 2016 Sep 10. J Hepatol. 2017. PMID: 27622858 Free article.
16 results